Dr. Neeraj Sharma, MD
What this data tells you about Dr. Sharma
Dr. Neeraj Sharma is a medical oncology specialist in Longview, TX, with 19 years of NPI registration. Based on federal Medicare data, Dr. Sharma performed 126,783 Medicare services across 4,820 unique beneficiaries.
Between the years covered by Open Payments, Dr. Sharma received a total of $3,969 from 30 pharmaceutical and/or device companies across 71 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in medical oncology. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Sharma is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
Medicare Practice Summary
Medicare Utilization ↗Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Iron infusion (Feraheme) | 35,700 | $0 | $5 |
| Darbepoetin injection (Aranesp) for anemia | 20,480 | $2 | $20 |
| Pembrolizumab injection (Keytruda) | 17,300 | $42 | $137 |
| Paclitaxel chemotherapy injection | 10,234 | $0 | $8 |
| Iron sucrose injection (Venofer) | 8,900 | $0 | $2 |
| Oxaliplatin chemotherapy injection | 6,400 | $0 | $33 |
| Contrast dye for imaging (iodine-based) | 6,194 | $0 | $3 |
| Dexamethasone injection (steroid) | 2,253 | $0 | $1 |
| Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg | 1,890 | $23 | $181 |
| Blood draw (venipuncture) | 1,847 | $8 | $20 |
| Complete blood count (CBC) with differential | 1,693 | $8 | $36 |
| Injection, atropine sulfate, 0.01 mg | 1,480 | $0 | $1 |
| Comprehensive metabolic blood panel | 1,314 | $10 | $64 |
| Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg | 1,160 | $21 | $155 |
| Office visit, established patient (20-29 min) | 742 | $60 | $250 |
| Injection, granisetron hydrochloride, 100 mcg | 720 | $0 | $24 |
| Anti-nausea injection (Aloxi/palonosetron) | 530 | $1 | $114 |
| Injection, fluorouracil, 500 mg | 513 | $2 | $13 |
| Injection, leucovorin calcium, per 50 mg | 499 | $3 | $25 |
| Injection, irinotecan, 20 mg | 482 | $2 | $210 |
| Office visit, established patient (30-39 min) | 459 | $89 | $368 |
| Administration of chemotherapy into vein, 1 hour or less | 383 | $97 | $707 |
| Injection, carboplatin, 50 mg | 320 | $2 | $300 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 283 | $22 | $157 |
| Ferritin level test (iron stores) | 268 | $13 | $60 |
| Iron level test | 268 | $6 | $27 |
| Iron binding capacity test | 268 | $9 | $35 |
| Injection of additional new drug or substance into vein | 247 | $12 | $108 |
| Lactate dehydrogenase (enzyme) level | 243 | $6 | $31 |
| Immunoglobulin level test | 228 | $9 | $56 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 180 | $54 | $211 |
| Injection, cisplatin, powder or solution, 10 mg | 154 | $2 | $94 |
| Drug injection, under skin or into muscle | 149 | $11 | $96 |
| Administration of additional new drug or substance into vein, 1 hour or less | 147 | $49 | $344 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 142 | $44 | $313 |
| Administration of chemotherapy into vein, each additional hour | 131 | $21 | $161 |
| Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3 | 129 | $20 | $128 |
| Microscopic examination for white blood cells with manual cell count | 124 | $4 | $22 |
| Complete blood count (CBC), automated | 124 | $6 | $34 |
| Injection, zoledronic acid, 1 mg | 122 | $6 | $431 |
| Reticulated (young) platelet measurement | 108 | $35 | $143 |
| Injection, diphenhydramine hcl, up to 50 mg | 106 | $1 | $7 |
| Injection, fosnetupitant 235 mg and palonosetron 0.25 mg | 90 | $338 | $1,722 |
| Infusion, normal saline solution , 1000 cc | 84 | $2 | $19 |
| Carcinoembryonic antigen (cea) protein level | 83 | $19 | $99 |
| Hospital follow-up visit, moderate complexity | 83 | $59 | $247 |
| Thyroid stimulating hormone (TSH) test | 82 | $16 | $80 |
| Intensity modulated treatment delivery, single or multiple fields/arcs,via narrow spatially and temporally modulated beams, binary, dynamic mlc, per treatment session | 82 | $272 | $2,762 |
| Basic metabolic blood panel | 80 | $8 | $49 |
| PSA test (prostate cancer screening) | 70 | $18 | $94 |
| Injection, magnesium sulfate, per 500 mg | 70 | $1 | $6 |
| Unclassified drugs | 70 | $1 | $8 |
| Vitamin B-12 level test | 61 | $15 | $76 |
| Folic acid level test | 61 | $14 | $73 |
| New patient office visit (45-59 min) | 58 | $112 | $565 |
| Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l | 57 | $123 | $500 |
| Enhancing oncology model (eom) monthly enhanced oncology services (meos) payment for eom enhanced services | 56 | $69 | $70 |
| Ct scan of chest with contrast | 52 | $44 | $821 |
| Irrigation of implanted venous access drug delivery device | 52 | $19 | $114 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 50 | $16 | $100 |
| CT scan of abdomen and pelvis with contrast | 48 | $159 | $1,067 |
| Injection of drug or substance into vein | 47 | $27 | $247 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 47 | $87 | $657 |
| Nuclear medicine study from skull base to mid-thigh with ct scan | 44 | $1,084 | $4,802 |
| Administration of additional new drug or substance into vein using push technique | 43 | $42 | $289 |
| Magnesium level test | 40 | $7 | $29 |
| New patient office visit, complex (60-74 min) | 38 | $160 | $709 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 36 | $23 | $145 |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 35 | $15 | $94 |
| Infusion into a vein for hydration, each additional hour | 33 | $10 | $75 |
| Chest X-ray, 2 views | 31 | $15 | $61 |
| Drawing of blood for a medical problem | 31 | $58 | $264 |
| CT scan of chest, without contrast | 30 | $57 | $686 |
| Infusion into a vein for hydration, 31-60 minutes | 25 | $24 | $256 |
| Initial hospital admission, high complexity | 24 | $133 | $694 |
| Radiation treatment delivery,3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 11-19 mev | 20 | $178 | $700 |
| Ct scan of abdomen and pelvis without contrast | 15 | $79 | $560 |
| Initial hospital admission, moderate complexity | 15 | $95 | $470 |
| Ct scan of soft tissue of neck with contrast | 13 | $73 | $658 |
| Stool analysis for blood to screen for colon tumors | 13 | $4 | $24 |
Industry Payment Transparency
Open Payments through 2024 ↗Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
Payments by company (2024)
Associated products mentioned in payments ›
The majority of payments (66%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in medical oncology and does not inherently indicate bias, but patients may wish to be aware.
Geographic Context
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Sharma is a mixed practice specialist, with above-average Medicare volume (top 6% in TX), with speaking/promotional industry engagement, with 19 years of NPI registration.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Sharma experienced with iron infusion (feraheme)?
Does Dr. Sharma receive payments from pharmaceutical companies?
How do Dr. Sharma's costs compare to other medical oncologists in Longview?
What does Data Coverage mean?
Is this data up to date?
Explore related providers
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology